Unity Biotechnology, Inc. (UBX)
NASDAQ: UBX · Real-Time Price · USD
0.9601
-0.0799 (-7.68%)
At close: Apr 1, 2025, 4:00 PM
1.039
+0.079 (8.24%)
After-hours: Apr 1, 2025, 4:38 PM EDT
Unity Biotechnology Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Unity Biotechnology stock have an average target of 5.33, with a low estimate of 4.00 and a high estimate of 8.00. The average target predicts an increase of 455.15% from the current stock price of 0.96.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Unity Biotechnology stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Buy | 1 | 1 | 1 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 2 | 2 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $6 → $4 | Strong Buy | Maintains | $6 → $4 | +316.62% | Mar 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $8 → $4 | Strong Buy | Maintains | $8 → $4 | +316.62% | Mar 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $8 → $4 | Strong Buy | Maintains | $8 → $4 | +316.62% | Mar 24, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $6 | Strong Buy | Maintains | $6 | +524.93% | Mar 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +733.25% | Mar 10, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
15.02M
EPS This Year
-1.30
from -1.54
EPS Next Year
-0.80
from -1.30
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 26.0M | 62.6M | ||
| Avg | n/a | 15.0M | 51.2M | ||
| Low | n/a | n/a | 40.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 316.6% | ||
| Avg | - | - | 240.7% | ||
| Low | - | - | 172.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.82 | -0.68 | -0.09 | ||
| Avg | -1.30 | -0.80 | -0.59 | ||
| Low | -1.60 | -0.98 | -1.05 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.